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Summary
Manypathogenicprokaryotesandeukaryotespossess
the machinery required to assemble galactofuranose
(Galf)-containing glycoconjugates; these glycoconju-
gates can be critical for virulence or viability. Accord-
ingly, compounds that block Galf incorporation may
serve as therapeutic leads or as probes of the function
of Galf-containing glycoconjugates. The enzyme UDP-
galactopyranosemutase (UGM) is the only knowngen-
erator of UDP-galactofuranose, the precursor to Galf
residues. We previously employed a high-throughput
fluorescence polarization assay to investigate the
Klebsiella pneumoniaeUGM.Wedemonstrate the gen-
erality of this assay by extending it to UGM fromMyco-
bacterium tuberculosis. To identify factors influencing
binding, we synthesized a directed library containing
a 5-arylidene-2-thioxo-4-thiazolidinone core, a struc-
ture possessing features common to ligands for both
homologs. Our studies offer a blueprint for identifying
inhibitors of the growing family of UGM homologs and
provide insight into UGM inhibition.
Introduction
Like other hexoses, galactose can exist in the thermody-
namically favored pyranose or the less favored furanose
form. Galactopyranose (Galp) residues are ubiquitous in
the glycolipids and glycoproteins of higher and lower
eukaryotes. Galactofuranose (Galf) residues are less
common, yet they are crucial components of the glyco-
conjugates in a number of pathogenic prokaryotes and
both uni- and multicellular eukaryotes [1]. Often, Galf-
containing conjugates are necessary for viability and/or
virulence. For example, Galf residues have been identi-
fied in the lipopolysaccharide (LPS) O-antigen of a num-
ber of gram-negative bacteria [2–10], and the O-antigen
is important in bacterial virulence [11]. There is also evi-
dence that Galf residues are essential components of
the cell wall of mycobacteria such as Mycobacterium
tuberculosis, the causative agent of tuberculosis (TB)
[12–14]. Galf residues have been identified in the glyco-
conjugates of a number of other organisms including
Salmonella spp. [15], Trypanosoma cruzi (the parasite
that causes Chagas disease) [16–18], and several fungi
including Aspergillus fumigatus [19–25]. Moreover,
Galf-containing glycoconjugates can be highly antigenic
in mammalian species because they are absent from
mammals [17, 24, 26]. The distribution and biological
*Correspondence: kiessling@chem.wisc.eduroles of Galf residues suggest that agents that block
the biosynthetic incorporation of Galf residues could
serve as valuable biological probes or therapeutic
agents [27].
UDP-galactofuranose (UDP-Galf) is the biosynthetic
donor of Galf residues. The only enzyme known to pro-
duce this sugar-nucleotide is UDP-galactopyranose
mutase (UGM or Glf). This enzyme catalyzes the isomer-
ization of UDP-galactopyranose (UDP-Galp) to UDP-Galf
(Figure 1A). It was first identified in prokaryotes, includ-
ing several gram-negative bacteria and mycobacteria
[8, 9, 28–32]. Prokaryotic UGM homologs share w40%
sequence identity; therefore, the putative genes encod-
ing these enzymes can be readily identified [32]. Eukary-
otic UGM homologs also share a high degree of identity;
however, they are only distantly related to their prokary-
otic counterparts [1]. Despite this challenge, strategies
for identifying eukaryotic UGMs have emerged recently
[1, 33]. For example, genes encoding UGM have been
identified in Leishmania major and Cryptococcus neo-
formans [1]. Genes that encode putative UGMs have
also been found in T. cruzi, Aspergillus fumigatus, and
the nematode Caenorhabditis elegans [1, 33].
Because UGM is a critical enzyme mediating Galf in-
corporation, we sought to identify small-molecule inhib-
itors. Such inhibitors could be used to probe four differ-
ent issues. First, they could uncover the importance of
Galf residues in the relevant organisms. Galf residues
are found in the glycoconjugates of a number of organ-
isms, yet the exact role that these residues play is often
unknown. A second and related issue arises from the
identification of genes encoding putative UGMs (glfs)
in species not yet known to utilize Galf [1]. For example,
Galf residues are not known to occur in C. elegans, but
a gene has been identified (H04M03.4) that encodes a
putative UGM. Genome-wide RNA interference screens
suggest that downregulation of the putative UGM is del-
eterious [34–36]. The function of this intriguing gene
product could be illuminated with inhibitors.
A third application of chemical probes of Galf metab-
olism is to validate a specific UGM as a therapeutic tar-
get. One compelling application of UGM inhibitors is as
antimycobacterial agents. Each year two to three million
people die as a result of infection with M. tuberculosis
[37]. The emergence of multidrug resistant strains of
M. tuberculosis is a major contributor to this death toll;
the need for new therapeutic agents is urgent. Several
of the drugs used to treat this disease, including isonia-
zid, ethionamide, and ethambutol [38–41], target cell
wall biosynthesis. Galf is a critical constituent of an im-
portant structural component of the mycobacterial cell
wall—the arabinogalactan. The arabinogalactan is cru-
cial for mycobacterial viability, suggesting that the en-
zymes involved in its biosynthesis, including UGM,
might serve as therapeutic targets [42]. In M. smegma-
tis, the genes encoding the enzymes that mediate Galf
incorporation are essential for growth [14]. This result
suggests that either the Galf-containing products of
these enzymes are critical or that the proteins them-
selves fulfill a structural role within a multiprotein
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entiate between these two possibilities; they can block
UGM activity and therefore Galf incorporation, but they
will not prevent potentially important protein-protein in-
teractions. Comparisons with other systems suggest
that small-molecule inhibitors can complement genetic
studies to illuminate the physiological role(s) or the ther-
apeutic value of a protein target [43].
A fourth use of chemical inhibitors is to illuminate the
catalytic mechanisms that underlie Galf residue incor-
poration. Previous results from our group indicate that
the UGM-mediated generation of UDP-Galf occurs by
a unique catalytic mechanism that involves a novel co-
valent flavin-galactose adduct [44]. Inhibitors could be
used to elucidate further details regarding the catalytic
mechanism. Additionally, they could provide insight
into the architecture of the substrate binding site. The
number and range of applications provide substantial
incentive to identify UGM inhibitors.
Blueprints for generating inhibitors of sugar-nucleo-
tide binding proteins, like UGM, are lacking. Although
the structures of several prokaryotic UGMs have been
determined by X-ray crystallography [45, 46], no struc-
ture of a substrate-enzyme complex has been reported.
Some substrate-based inhibitors have been described,
including sugar analogs and uridine derivatives [47–
51]. However, the similarity of these to the natural sub-
strate suggests they will inhibit enzymes that operate
on related substrates. More broadly, few inhibitors of
any sugar-nucleotide binding proteins have been re-
ported; thus, we could not rely on known small-molecule
scaffolds.
We reasoned that potent and selective inhibitors of
UGM could be discovered from large, structurally diverse
libraries of compounds. Recently, we reported the devel-
opment of a fluorescence polarization-based high-
throughput assay for UGM from the gram-negative bac-
terium, K. pneumoniae (UGMKleb) [52]. Using this assay,
we identified several UGM ligands. Here, we evaluate
the generality of this assay by testing its utility for identi-
fying ligands of UGM from M. tuberculosis (UGMMyco).
We anticipate that the identification of ligands for UGM
homologs from different organisms will afford com-
pounds that exhibit activity against a range of prokary-
otic and perhaps even eukaryotic UGMs.
Figure 1. Nucleotide-Sugar Isomerization Reaction and Structure
of Fluorescent Probe 1
(A) UGM catalyzes the isomerization of UDP-Galp and UDP-Galf.
(B) A fluorescent probe (1) based upon UDP was developed for
fluorescence polarization assays.We have found several compounds with activity
against both UGMMyco and UGMKleb. These compounds,
along with those selective for a single UGM homolog,
are structurally similar: they contain a five-membered
heterocyclic core functionalized with a 1,3-display of
substituents. To optimize the potency of these leads
and to further investigate the interactions necessary
for UGM-ligand binding, we synthesized a directed li-
brary based upon a 2-thioxo-4-thiazolidinone scaffold.
Evaluation of the directed library provided insight into
the requirements for UGM binding.
Results and Discussion
Conventional screens for enzyme inhibitors involve the
assessment of catalytic activity. UGM activity is most ac-
curately monitored by following the production of UDP-
Galp by high-pressure liquid chromatography (HPLC).
This assay cannot be adapted readily to screen large
numbers of compounds, and we envisioned that a fluo-
rescence polarization (FP) assay could fulfill that require-
ment. Fluorescence polarization (FP) binding assays are
readily adaptable to high-throughput screening; they
require minimal sample manipulation and are highly sen-
sitive. In FP, the emission of a fluorescent compound
excited with plane-polarized light is measured. For as-
sessing ligand binding to UGM, polarization readings
depend upon whether the fluorescent probe is bound
to UGM (tumbling slowly, high polarization) or free in so-
lution (tumbling rapidly, low polarization). A compound
that displaces the fluorescent probe from its binding
pocket will cause the latter state. Because FP assays
can detect complexes with a wide range of dissociation
constants, they are proving to be especially useful for
glycobiology studies. For example, FP has been applied
to study lectin binding [53, 54] and to identify inhibitors of
two other enzymes, MurG and O-GlcNAc transferase,
that act on UDP-sugar substrates [55, 56].
Identifying UGMKleb Ligands
Previously, we reported using an FP assay to screen a
library of 16,000 diverse small molecules designed to
be cell permeable (Chembridge DIVERSet) against
UGMKleb [52]. We have subsequently screened an addi-
tional 20,000 compounds (Chemical Diversity Labs,
ChemDiv) against this enzyme. The compounds used
in this screen were chosen to complement chemical di-
versity of those tested previously. These experiments,
therefore, provide additional information on the types
of molecular scaffolds that bind UGM.
We screened all compounds at a final concentration of
33 mM in a solution of the fluorescent probe 1 (Figure 1B)
and UGM. To calibrate the FP values within each 384-
well plate, we included wells containing compound 1
alone and compound 1 and UGMKleb. Data from all com-
pounds with intrinsic fluorescence (<1%) were omitted.
As a positive control, we also included a well containing
UDP along with UGM and the fluorescent probe. We had
shown previously that UDP is a ligand for UGM and had
determined a Kd of 8.8 mM for the complex; we sought
to identify compounds that interact with comparable
or superior affinity. Approximately 0.4% of the com-
pounds from both libraries were identified as hits (FP
values less than or equal to those obtained for UDP).
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centration, and dissociation constants for the most ac-
tive compounds were determined to identify the best
binders (Figure 2A).
Identifying UGMMyco Ligands
We sought to explore the generality and specificity of
the compounds identified as UGMKleb ligands and the
generality of our assay. To ascertain whether our FP as-
say would be useful with other UGM homologs, we
tested it with the UGM from M. tuberculosis (UGMMyco).
For these studies, we needed to produce adequate
quantities of UGMMyco. Although it can be difficult to
produce mycobacterial proteins in E. coli, we used a
procedure similar to that employed for production of
a UGMKleb [52]. We generated a construct encoding
UGMMyco bearing a C-terminal hexahistidine tag (His6).
To produce this tagged protein, we allowed cultures to
grow overnight without induction (no isopropyl-b-D-thi-
ogalactopyranoside); this procedure provided UGMMyco
in good yields (7 mg per liter of culture).
With UGMMyco in hand, we sought to evaluate the gen-
erality of our high-throughput FP assay. To this end, we
measured the affinity of UGMMyco for fluorescent probe
1. Given the high sequence similarity between the homo-
logs (w40%), we anticipated that the binding affinity for
UGMMyco would be similar to that for UGMKleb. Indeed,
the Kd value was determined to be 0.16 6 0.005 mM
for the complex of 1 and UGMMyco, a value that is com-
parable to the Kd of the UDP fluorescein derivative (1)-
UGMKleb complex (w0.10 mM). We also determined
that UDP could competitively displace 1. Finally, the
IC50 value for 1 with UGMMyco was determined to be
5.7 mM. These data confirm that the established FP as-
say could be applied to identify ligands for UGMMyco.
Both commercially available libraries were screened
by the aforementioned procedure. These screens
afforded 55 active compounds from the ChemBridge
library (0.3% hit rate) and 25 from the ChemDiv library
(0.15% hit rate). As with UGMKleb, compounds active in
the initial screen were tested at a 10-fold lower concen-
tration, and the dissociation constants were determined
for the best ligands (Figure 2A). Although compounds 9
and 10 were not identified as hits in the initial screens
against UGMKleb, further analysis revealed that they
are ligands for this enzyme (Kd values = 1.9 6 0.2 and
1.7 6 0.1 mM, respectively). These results highlight the
utility and generality of our FP assay.
Analysis of Identified Ligands
A number of the identified compounds can bind to either
enzyme homolog (compounds 6, 9, and 10) (Figure 2A).
Moreover, many of the identified UGM ligands share
structural features (e.g., compounds 5, 6, 8, 9, 10). These
features include a five-membered thiazolidinone core
that displays two carbonyl or carbonyl-like (e.g., thiocar-
bonyl or imino) hydrogen bond acceptors and a 1,3-ar-
rangement of substituents on the heterocyclic core.
Although other structures can serve as ligands for en-
zymes that act on sugar-nucleotide substrates [56],
compounds with thiazolidinone cores have been identi-
fied as ligands for UDP- or TDP-sugar utilizing enzymes,
including the glycosyltransferase MurG [55] and the
NADPH-dependent enolpyruvyl reductase MurB [57, 58].Several research groups have hypothesized that these
heterocycles may function as diphosphate mimics
[55, 57, 59]. We speculate that they have shapes that
favorably occupy the nucleotide-sugar binding site.
In addition to the common orientation of substituents
on the thiazolodinone core, analysis of the active com-
pounds revealed other common themes. Most of the
substituents are aromatic groups [55, 57]. We hypothe-
sized that one of these occupies the site of the pyrimidine
base in the natural substrates. In UGM, for example, we
speculate that one aromatic inhibitor substituent mimics
the uracil ring in UDP-Galf by engaging in p-stacking
interactions with an active site tryptophan (Trp166Myco)
[45]. The UGM inhibitors identified in our screen all pos-
sess an additional aromatic group. Interestingly, a uri-
dine-derived compound that possesses an aryl moiety
linked to the 50 position has been identified as a UGM
inhibitor in a different assay (IC50 = 6 mM) [51]. We postu-
late that the second aromatic substituent interacts with
the polarizable isoalloxazine ring system of the flavin
cofactor [60]. The dramatic increase in binding affinity
(40-fold) for fluorescein derivative 1 over UDP provides
support for such a model; it suggests that UGM can
Figure 2. Compounds Identified from the High-Throughput FP
Screen of Two Commercially Available Compound Libraries
(A) Ligands for UGMKleb and UGMMyco are depicted. Although com-
pounds 9 and 10 were not identified as ligands of UGMKleb in the
initial screen, they were later found to have activity against this
enzyme with Kd values of 1.9 6 0.2 and 1.7 6 0.1 mM, respectively.
Kd values are reported as mean 6 standard error for triplicate
experiments.
(B) Examples of inactive yet structurally similar compounds present
in the libraries.
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actions.
To further explore the binding requirements of UGM
and to optimize the potency of our probes, we synthe-
sized a directed library. We selected the thiazolidinone
derivative 6 as the core scaffold because it possesses
the key features of our most active compounds; it also
has activity against both UGMKleb and UGMMyco. An
additional advantage of using this scaffold is that a
solid-phase route had been described for 2-thioxo-4-
thiazolidinone (or rhodanine) heterocycles [61].
To aid in the design of a directed library, we examined
the structures of both the identified ligands and structur-
ally similar but inactive compounds (Figures 2A and 2B).
We first looked at which substituent varied most, with
a goal of orienting the ligands in the UGM binding site.
Our data indicate that the sugar binding site in UGM
can accommodate a variety of groups including the
structurally different Galp and Galf residues and the
fluorescein-containing linker. We therefore reasoned
that the most variable substituent would occupy this re-
gion of the substrate binding site. Because the R2 moie-
ties (14) (Figure 3) vary in both size and functional groups,
we propose that this portion of the ligands occupies the
sugar binding region. In contrast, little variation is toler-
ated at R1. Compounds containing large or aliphatic
groups at this position are inactive; therefore, we hypoth-
esize that the R1 group acts as a uracil or uridine mimic.
This model guided the design of our directed library.
Directed Library Design, Synthesis, and Screening
The organic chemistry of thiazolidinones has a rich his-
tory [62–66]. Interest in the synthesis of compounds in
this class has been driven by their biological activities.
Indeed, several antidiabetic drugs contain thiazolidi-
none heterocycles, including rosiglitazone and pioglita-
zone [67]. Thiazolidinone-based compounds are also
under investigation as anti-inflammatory [68, 69], antivi-
ral [70], antibacterial [71], and anticonvulsant agents
[72]. Given these activities, a number of different strate-
gies have been developed for the formation and func-
tionalization of the thiazolidinone heterocycles [65, 66].
As described above, we elected to synthesize a directed
library based upon the 2-thioxo-4-thiazolidinone (or rho-
danine) core. To facilitate the rapid assembly of com-
pound libraries, we sought to implement a solid-phase
synthetic strategy.
In 2000, Lee et al. described a solid-phase route to
2-thioxo-4-thiazolidinones [61]. This strategy yields
compounds with the substitution pattern of our most ac-
tive compounds; therefore, it provided a launching point
for developing our synthetic route. To synthesize the
core heterocycle, Lee et al. used an immobilized primary
amine, such as 12. Species of this type can readily be
generated by removal of an Fmoc group from an amino
acid immobilized on resin. The amine can then be ex-
posed to thiocarbonyl diimidazole to generate the thio-
urea (Figure 3). Subsequent treatment with methyl thio-
glycolate yields the rhodanine heterocycle (13). We
synthesized the immobilized heterocycle by using a
similar protocol. We found, however, that the products
synthesized with Wang resin were not as pure as those
generated from 2-(4-bromomethylphenoxy)ethyl poly-
styrene resin.The most problematic step in the published route is
the addition of an arylalkylidene moiety, which was ac-
complished by a Knoevenagel condensation to afford
products 14. The desired process was effected by ex-
posing the heterocycle to carbonyl compounds in re-
fluxing toluene. These transformations are sluggish:
the reactions of aldehydes require 12 hr and those of
ketones 3 days in the presence of ammonium acetate.
These conditions are inconvenient for solid-phase syn-
thesis, so we sought alternatives.
A variety of conditions to effect Knoevenagel conden-
sations have been reported. Often this reaction is per-
formed at high temperatures and in the presence of
a strong acid or base [66]. These conditions are not ap-
propriate for solid-phase synthesis because they utilize
strong acid, which is generally used to cleave com-
pounds from resin, or aqueous solvent, in which most
resins do not swell efficiently. Additionally, virtually all
of these conditions require long reaction times and
high temperatures. The problems of slow reaction kinet-
ics are exacerbated in solid-phase synthesis, but micro-
wave irradiation can be used to ameliorate such prob-
lems [73]. Specifically, it is well known that microwave
irradiation can dramatically increase the efficiency of
synthetic steps, especially those that require heat, like
the desired transformations. Indeed, microwave irradia-
tion has been used successfully to promote the Knoeve-
nagel reaction in solution [74–76]; we reasoned it should
have an even greater impact on the solid-phase reaction.
To test this hypothesis, we used a model reaction be-
tween the phenylalanine derivative of intermediate 13
and m-bromobenzaldehyde. To optimize this process,
we varied the time of irradiation, temperature, and watt-
age employed. With microwave irradiation (70C, 100
watts, toluene, and piperidinium acetate), the reaction
of the rhodanine heterocycle with both aldehydes and
ketones proceeds to completion in only 10 min (Figure 3).
These conditions are a dramatic improvement over
those utilized previously, and they facilitated the assem-
bly of the directed library.
In our focused library, we varied R1 and R2 to assess
their roles in binding. Our pharmacophore model sug-
gests that R1 must be an aromatic moiety. As mentioned
above, we hypothesized that this aromatic substituent
interacts with a highly conserved active site tryptophan
and that this interaction is critical for ligand binding. To
investigate the role of this aromatic group, we generated
Figure 3. Synthetic Route to the Directed Library
Adaptation of the published solid-phase route to rhodanines
included the development of microwave irradiation conditions to
increase the efficiency of the Knoevenagel condensation.
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OHN
OS
S
O
R2 R1
Compound R1 R2
UGMKleb
Kd (mM)
UGMMyco
Kd (mM)
15 H Br >33 >33
16 CH3 Br >33 >330
17
OH
Br 11.2 >33
18 H
HN
O >33 >330
19 CH3
HN
O >33 >330
20
OH
HN
O 14.1 >33
21 Cl 21.3 16.0
22 I 6.3 6.0
23 F >33 >33
24 Br >33 9.3
25 Br >33 >33
26 NO2 >33 >33compounds 15–20, in which the R1 group is varied (Table
1). For comparison, these compounds contain the R2
moieties identified in the two lead compounds (6 and 8).
To explore the R2 binding site, we synthesized ten
additional compounds (Table 1). Our binding model sug-
gests that diversification of the arylalkylidene moiety will
be tolerated by UGM. To evaluate the binding contribu-
tions of different R2 moieties, we generated a series of
compounds incorporating the R1 group found in both
of the lead structures but with different R2 groups. The
majority of the R2 diversity elements included in this li-
brary was selected to explore the importance of the
m-bromo substituent in compound 6. We postulated
that the electron-withdrawing properties of this halogen
contribute to binding. Thus, we chose to synthesize
m-chloro, m-iodo, m-fluoro-, and m-nitro derivatives
as well as p- and o-bromo substituted compounds
(21–26). Additionally, compounds bearing substituents
with different electronic properties were also examined
including m-methyl-, m-methoxy-, and unsubstituted
analogs (27–29). Finally, a substituted isatin derivative
(30) was synthesized to explore the binding mode of
compound 8.
These compounds were assembled by using the
aforementioned synthetic route (Figure 3). Upon cleav-
age from the resin, the target compounds were obtained
in w60%–75% overall purity, as measured by liquid
chromatography-mass spectrometry (LC-MS). The
Table 1. Continued
OHN
OS
S
O
R2 R1
Compound R1 R2
UGMKleb
Kd (mM)
UGMMyco
Kd (mM)
27 >33 >33
28 OMe >33 >33
29 >33 >33
30
HN
O
NO2
5.7 10.0
31 none >33 >330
32 No N
substitution
Br >330 >330
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(C18) microcolumn to afford products of high purity (94%
of the compounds wereR80% pure,w20%–30% yield).
All compounds were obtained with a single double-bond
geometry. The condensation reactions with aldehydes
yielded only the Z isomer, as determined by the chemi-
cal shift of the methylene proton [77, 78]. The ketone-de-
rived compounds were assumed to also be the thermo-
dynamically more stable Z isomer (attempts to obtain
crystals of these compounds for X-ray analysis were
unsuccessful). Analysis of the library members by chiral
high-performance liquid chromatography (HPLC) re-
vealed that the configuration of the stereogenic carbon
in the amino acid building blocks (Phe, Tyr, Ala) was
not preserved in the products [61]. Thus, enantiomeric
mixtures of all library members were assayed.
Two additional compounds, 31 and 32, were added to
the library to explore the necessity of the R1 and R2 sub-
stituents (Table 1). A compound lacking an R2 substitu-
ent, 31, was easily obtained because it is an intermediate
(13) in the solid-phase synthetic route to compounds 14.
Compound 32, which has no R1 moiety, was synthesized
in solution using a published protocol [79].
The resulting library, which was composed of 18 com-
pounds, was screened in our FP assay. As described
previously, each compound was dissolved in DMSO
and added to a mixture of UGMMyco or UGMKleb and the
fluorescein probe, 1. All compounds were tested initially
at a final concentration of 330 mM, and those with activity
were subsequently examined at 33 mM. From the di-
rected library, we identified five compounds that bound
to UGMKleb (17, 20, 21, 22, 30) and four with significant
affinity for UGMMyco (21, 22, 24, 30 in Table 1). Of these,
three were ligands for both UGM homologs (21, 22, 30).
To prepare material for further analysis, each compound
that had been obtained in <94% purity during initial
library generation was resynthesized and purified by
HPLC. FP was then used to determine the dissociation
constant of each active compound (Table 1).
The Kd value obtained for each of the active com-
pounds is a measure of its ability to bind UGM. To assess
the ability of these compounds to inhibit the catalytic ac-
tivity of UGM, we employed an HPLC assay [52]. Inhibi-
tion constants (IC50) were determined by monitoring
UGM activity at a single substrate concentration while
varying inhibitor concentration (Table 2). The data reveal
that compounds with similar Kd values did not always
have similar IC50 values. For example, compounds 6
and 8 have Kd values of approximately 10 mM (UGMKleb),
but their IC50 values are 1.6 and 93 mM, respectively. We
postulated that these differences might arise from mod-
ification of the 5-arylidene-4-thiazolidinone derivatives.
We were especially interested in the reactivity of these
heterocycles under conditions relevant to those in vivo
because compounds of this type possess diverse and
valuable biological activities.
5-Arylidene-4-Thiazolidinone Reactivity
5-Arylidene-4-Thiazolidinones have been identified as li-
gands for important proteins and enzymes; several of
these compounds are under investigation as therapeutic
agents [55, 59, 66, 68, 69, 80–84]. Interestingly, some
thiazolidinones have been shown to undergo ‘‘photo-
chemically enhanced’’ binding to their targets [85, 86].Specifically, Decicco and coworkers reported that sev-
eral of the thiazolidinones they identified as tumor necro-
sis factor receptor-1 (TNFRc1) inhibitors displayed bind-
ing properties that depend upon light. When light is
present, these compounds form covalent bonds to their
protein targets. All of the compounds exhibiting this
light-sensitive reactivity possess extended p systems.
The general relevance of this photochemical reactivity
to most thiazolidinone inhibitors is not apparent.
We focused on another potential mode of 5-arylidene-
4-thiazolidinone reactivity. Inspection of the 5-arylidene-
4-thiazolidinone structure suggests these compounds
can serve as electrophiles. Indeed, they can undergo
conjugate addition reactions with nucleophiles to afford
adducts such as 33 (Figure 4) [87–90]. Still, thiazolidi-
nones have been identified as inhibitors in cell-based
screens, in which physiological nucleophiles, like the
thiol glutathione, are present at high concentrations.
We therefore sought to determine whether the 5-aryli-
dene-4-thiazolidinones react under conditions relevant
for their biological activity.
We tested whether two representative thiazolidi-
nones, compounds 6 and 8, undergo conjugate addition
reactions under relevant conditions—aqueous solution
at neutral pH in the presence of reducing agents (thiols).
To this end, we used ultraviolet-visible spectroscopy.
We reasoned that any conjugate addition process would
result in a spectral change that could readily be de-
tected. To test their reactivity, the compounds were dis-
solved in sodium phosphate buffer and the UV spectra
obtained. As our reducing agent and thiol, we employed
dithiothreitol (DTT), which was added to the compound
solution at the same concentration used in assays of the
catalytic activity of UGM [46]. Upon DTT treatment, a sig-
nificant decrease in the absorbance of the maximum
peak (380 nm for compound 6 and 425 nm for compound
8) was observed in less than 1 min (data not shown). No
additional change was observed after an hour of incuba-
tion. This decrease in absorbance intensity is indicative
of the loss of an extended chromophore, and is consis-
tent with the 1,4-conjugate addition of DTT. Additionally,
analysis by LC-MS revealed the formation of a species
with the expected m/z of adduct 33 ([M 2 H] expected
601.97, observed 601.9). To determine if all related rho-
danine-containing compounds were reactive in our as-
say, we examined compounds 16, 23, 28, and 29, which
possess substituents with differing electronic proper-
ties. All compounds tested underwent rapid reaction.
Our data indicate that 5-arylidene-4-thiazolidinones
are reactive under physiological conditions. In addition,
Table 2. Selected IC50 Values
Compound UGMKleb IC50 (mM) UGMMyco IC50 (mM)
5 17 —
6 1.6 65
7 4.6 —
8 93 —
9 4.0 41
10 4.0 28
21 n/d 49
22 n/d 41
24 — 35
30 n/d >100
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Rhodanine-containing compounds (6) can react with thiols by 1,4-conjugate addition into the exocyclic double bond (33) under physiological
conditions. UV-Vis spectroscopy studies show that this reaction is reversible. Examination of the UV-Vis spectra of compound 6 before and
after addition of DTT is presented. Over time, DTT oxidation results in reformation of starting compound 6. Complete restoration was seen in
approximately 2 days. The increased absorbance at 290 nm is due to oxidized DTT.they suggest that, when DTT is added to reduce UGM,
adducts (e.g., 33) form in the course of the assay. Never-
theless, the thiazolidinones inhibit UGM, and given the
structure of this enzyme, we suspected that the DTT
adducts (e.g., 33) would not bind. Moreover, it seems
unlikely that all of the thiazolidinone inhibitors identified
in other cell-based assays function as thiol adducts.
Thermal conditions in organic solvents that promote
reversible conjugate addition reactions have been re-
ported [88]; however, we sought to determine whether
reversion occurs under more physiologically relevant
conditions.
To test for the reversibility of thiol addition, compound
6 was mixed with DTT and allowed to react in the pres-
ence of oxygen. If the reaction is reversible, the starting
compound 6 will be regenerated over time by oxidative
consumption of DTT. After only 4 hr, the regeneration
of thiazolidinone 6 was observed by UV-Vis spectros-
copy (Figure 4). After 2 days, the starting material 6
was the only product obtained. Thus, the addition reac-
tion of thiols to 5-arylidene-4-thiazolidinones is revers-
ible in aqueous solutions. This result suggests that the
parent compounds are the UGM inhibitors and that the
observed discrepancies between the Kd and IC50 values
are due to a decrease in the concentration of the active
species in the assay. Moreover, the results indicate that
differences in assay conditions might afford very differ-
ent results in screens of compound collections contain-
ing 5-arylidene-4-thiazolidinone derivatives.
We performed additional experiments to probe the
impact of the reversible conjugate addition reaction on
our inhibition data. First, the inhibition constant of com-
pound 24 was determined under several different con-
ditions. Typically, the activity assay is carried out by
mixing the inhibitor and the substrate in assay buffer(containing DTT); UGM is then added to initiate conver-
sion. Under these conditions, the IC50 value for com-
pound 24 is 35 mM (UGMMyco). We performed experi-
ments in which the order of addition of the various
assay components was altered. In one experiment,
UGMMyco, 24, and DTT were incubated in buffer for 10
min before UDP-Galf was added to initiate the enzy-
matic reaction. A parallel experiment was performed in-
volving a 10 min incubation of enzyme and 24 followed
by simultaneous addition of DTT and UDP-Galf. Expo-
sure of the inhibitor to DTT prior to incubation with
UDP-Galf gave an IC50 value of 50 6 7 mM, but when no
pretreatment was employed, an IC50 value of 39 6 4 mM
was obtained. These results also indicate that the inhib-
itory species is compound 24 and not its DTT adduct.
Our studies suggest that the reactivity of 5-arylidene-
4-thiazolidinones complicates their use in cell-based as-
says or in vivo; they can react with glutathione or other
free thiols within a cell. Indeed, we found that compound
6 reacts with physiologically relevant concentrations of
glutathione (0.5–10 mM). Our data also indicate, how-
ever, that the compounds identified in our screen are
the active species. The observed differences between
our Kd and IC50 values likely arise from a decrease in
the effective concentration of these inhibitors in the as-
say solution. These issues, however, do not complicate
analysis of the data on UGM binding.
Features of UGM Ligands
Our original model predicted that two aromatic substitu-
ents are necessary for effective interaction with UGM. As
mentioned previously, we hypothesized that R1 acts as
a uracil mimic and that it participates in aromatic-aro-
matic interactions. The weak affinity of the glycine and al-
anine-derived compounds (15, 16, 18, and 19) for UGM is
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that, when R1 is a phenol (17 and 20), the resulting
compounds interact favorably with UGMKleb but not
UGMMyco. Thus, these enzyme homologs manifest sub-
tle differences in their binding preferences.
The majority of the UGM ligands identified display
halogen substituents at the R2 position. Halogens can
influence ligand binding interactions through different
means, including van der Waals and electrostatic inter-
actions. Interestingly, halocarbons, especially aryl and
heteroaryl halides, can participate in halogen-bonding
interactions (noncovalent interactions that involve halo-
gens as electron acceptors) [91, 92]. Halogen substitu-
ents can also dramatically affect the polarizability of a
ligand and thereby alter its binding properties. We antic-
ipate that the halogen groups in the active 5-arylidene-4-
thiazolidinones alter both the polarizability of the aryl
moiety and the extended p system.
To probe the importance of the electronic properties of
the halogen substituents, we generated 27, which pos-
sesses a methyl group, a substituent of similar size to
a bromo group but with dramatically different electronic
properties. The affinity of this compound for UGM is
weak. This result suggests that binding affinity depends
not only on the size of the halogen substituent but also on
its electronic properties.
We also examined the importance of the electronega-
tivity of the halogen substituent by testing a series of
compounds with electron-withdrawing substituents on
the aryl ring. We found that compounds containing nitro
(26) or fluoro (23) groups were less effective ligands than
bromo derivative 6. These results indicate that the role of
the halogen substituent goes beyond its ability to act
as an electron-withdrawing group. The ability of com-
pounds bearing m-chloro (21), bromo (6), or iodo sub-
stituents (22) to bind UGM suggests that UGM is not ex-
quisitely sensitive to the size of the halogen. The two
UGM homologs, however, appear to differ in their pref-
erence for the placement of the bromo substituent.
The derivative with a p-bromo aryl substituent (24) binds
to UGMMyco with similar affinity as the lead structure (6).
However, UGMKleb has a weaker affinity for this analog.
The o-bromo-containing compound (25) does not bind
to either enzyme. This difference in affinity likely arises
from steric interactions between the large o-bromo
group and the rhodanine heterocycle, which will influ-
ence the conformation of25. Finally, the failure of the me-
thoxy-substituted compound (28) and the unsubstituted
derivative (29) to bind tightly to UGM is consistent with
our conclusions that the electronic properties of the
aryl halide influence UGM-ligand interactions.
Isatin-derived thiazolidinone derivatives are also ef-
fective ligands for UGM (compound 30 and lead struc-
ture 8). This finding is consistent with our hypothesis
that the enzyme can accommodate a range of diverse
functionality at the R2 position. Interestingly, the isatin-
derived compounds display the greatest discrepancy
between their Kd and IC50 values. When exposed to
DTT, compound 8 is almost completely consumed,
which suggests that its relatively poor IC50 values stem
from its greater propensity to form the DTT adduct.
Additional support for our binding model was attained
by examining the activities of compounds 31 and 32,
which represent each of the two ‘‘halves’’ of the leadstructure. Neither the compound possessing only the
R2 (32) nor the R1 (31) bound to UGM. Comparing the
conformations of these two molecules with that of the
lead compound 6 revealed no obvious conformational
differences. Together, the data indicate that both por-
tions of the lead structure are required for binding.
Modeling Substrate and Ligand Interactions
with UGM
With no structural information about the substrate-UGM
complex, mutagenesis and our binding data provide in-
sight into the interactions important for binding of the
sugar-nucleotide. Several amino acid side chains are
thought to be critical for substrate binding in UGMMyco
including Trp166, Tyr161, Tyr191, Tyr328, His68,
Gln165, Phe192, Asn282, Arg261, and Arg292 [46];
Trp166 and the tyrosine residues are necessary for effi-
cient catalysis [46]. The former is thought to participate
in p-stacking interactions with the uracil moiety of the
substrate. Additionally, the tyrosine side chains may in-
teract with the two sugars, ribose and galactose. Finally,
several conserved arginine residues may engage in crit-
ical contacts with the substrate pyrophosphate group.
These residues form a pocket near the isoalloxazine
ring system of the flavin that is believed to be the active
site of UGM. Docking the substrate UDP-Galp into the
putative active site suggests that the sugar moiety is
proximal to the flavin isoalloxazine ring system (Fig-
ure 5). These results are consistent with other models
of the complex [93].
Modeling studies were conducted to visualize poten-
tial binding interactions between UGMMyco and active
compound 6 (Figure 5). Compound 6 was manually
docked into the active site; it was placed near side
chains implicated in substrate binding. Examination of
the resulting model reveals that the ligand 6 is similar
in size to the natural substrate, UDP-Gal. Additionally,
heterocycle 6 is well positioned to take advantage of
many putative substrate-protein interactions, such as
p stacking between the R1 moiety and Trp166. The rho-
danine moiety may participate in hydrogen bonding in-
teractions with the protein (such as Arg261 and
Arg292) in a manner similar to that of the diphosphate
moiety. Finally, the R2 substituent could interact with ac-
tive site side chains (such as Tyr, His, and Phe residues)
and the flavin isoalloxazine ring system. We anticipate
that this model for UGM-ligand binding will aid in the
future design of effective inhibitors of this enzyme.
Significance
Although Galf residues are often incorporated into
structures important for the viability or virulence of
anorganism, determining the precise function of these
sugar moieties is difficult. The identification of agents
to probe the enzymes involved in the biosynthesis of
Galf-containing glycoconjugates, including UGM, will
illuminate the functions of this unique and important
sugar. Using a high-throughput binding assay that
is effective for several UGM homologs, including
UGMMyco, we identifiedof a number of ligands for these
enzymes. Several of the identified compounds are
strikingly similar in structure, containing a five-mem-
bered heterocyclic core and a 1,3-substituted display
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Site
Left, model from manual docking of the nat-
ural substrate UDP-Galp into the putative
active site. The substrate was placed near
to amino acids thought to be critical for bind-
ing (Trp166 shown in dark yellow). This
model suggests that the sugar may bind in
close proximity to the isoalloxazine ring of
the flavin cofactor (purple). Right, docking
of lead 6 indicates that this compound is
very similar in size to the natural substrate.of aromatic substituents. The similarity of the com-
pounds identified for both UGMMyco and UGMKleb sug-
gests that probes possessing this substituent display
may interact with many or all prokaryotic UGMs; thus,
compounds should emerge that can reveal the roles
ofgalactofuranose incorporation inanumberof organ-
isms. In addition to the utility of identified ligands for
study in prokaryotic organisms, we anticipate that
the presented data will enable the development of
probes for eukaryotic UGMs. We envision that such
ligands could be used to elucidate the physiological
roles of Galf incorporation. Interestingly, we deter-
mined that 5-arylidene-4-thiazolidinone compounds,
which have been identified as ligands of UGM and
manyother proteins, reactwith thiols under physiolog-
ical conditions. Experiments to determine the efficacy
of the identified compounds in a cell-based assay are
ongoing and data from these experiments will illumi-
nate the significance of the observed thiol reactivity.
We also anticipate that the ligands identified here can
be used to assess the validity of UGM as a potential
target for antimycobacterial agents.
Experimental Procedures
Procedures for the production of UGMKleb, determination of binding
constants and IC50 values are available in Supplemental Data, as
these procedures have been published previously [44, 52].
Protein Production UGMMyco
Deoxyoligonucleotide primers for polymerase chain reaction (PCR)
were obtained from the University of Wisconsin Biotechnology Fa-
cility. Restriction endonucleases and polymerases were purchased
from either New England Biolabs or Promega. Nickel-nitrilotriacetic
acid (Ni-NTA) resin was obtained from Qiagen.
A pET-29b(+) construct containing the cloned gene encoding
UGM, glf, from Mycobacterium tuberculosis was generously pro-
vided by James Naismith (University of St. Andrews) [46]. A sequence
encoding a hexahistidine (His6) tag was added at the 3
0 end of the
amplified gene by PCR, and the DNA was digested with DpnI (Prom-
ega, Madison, WI) and transformed into E. coli DH5a, giving pET29b:
UGMMyco-His6. The final construct was then transformed into E. coli
BL21(DE3) cells. Transformed cells were grown in 4 ml LB broth
containing 50 mg/ml kanamycin at 37C, and the overnight culture
was used to inoculate 1 liter of terrific broth containing 50mg/ml kana-
mycin, which was then incubated overnight at 37C. Cells were har-
vested by centrifugation and resuspended in sodium phosphate
buffer (20 mM, pH 7.4) containing 500 mM NaCl and 25 mM imidazole.
Cells were disrupted via treatment with lysozyme and Triton X-100(0.1% v/v). The resuspended cells were left on ice for 1 hr and then
broken by sonication (50% duty cycle, 6 cycles of 1 min on then 2
min off, Branson 450 sonifier). Lysed cells were centrifuged at
16,000 3 g for 50 min at 4C.
The protein was purified in one of two ways: His6-Ni-NTA agarose
affinity chromatography or fast protein HisTrap HP liquid chromatog-
raphy (FPLC). In the former case, the cell resuspension buffer used
was 50 mM sodium phosphate (pH 8.0) containing 20 mM imidazole
and 300 mM NaCl, and the supernatant fraction was applied to a
Ni-NTA column (Qiagen, Valencia, CA), and the column was washed
with the aforementioned resuspension buffer. To elute UGM, 50 mM
sodium phosphate buffer (pH 8.0) containing 250 mM imidazole was
added. The mass of purified UGM was analyzed by MALDI-TOF MS
(expected m/z: 48,445.31; observed m/z: 48,435.60). In the latter
case, the supernatant fraction was applied to a 1 ml HiTrap HP col-
umn (Amersham Biosciences, Piscataway, NJ), and the column
was washed with the resuspension buffer. Bound protein was eluted
in a linear gradient (0%–100%, 10 column volumes) to 20 mM sodium
phosphate buffer (pH 7.4) containing 500 mM NaCl and 500 mM im-
idazole. Fractions containing purified UGM were pooled. Both
methods provide an average yield of 7 mg of purified enzyme from
1 liter of culture.
Order of Addition Activity Assays
To a 50 mM sodium phosphate buffer (pH 7.0), UGMMyco (12 mg) and
compound were mixed. DTT was added (to 20 mM final concentra-
tion) to some samples. Samples with and without DTT were incu-
bated 10 min at room temperature, after which DTT was added to
the relevant samples to afford a final concentration of 20 mM;
UDP-Galf was added to a final concentration of 50 mM. The total
reaction volume was 60 ml. Reactions were incubated at 37C for
10 min, and then 60 ml of 1:1 MeOH:CHCl3 solution was added to
quench the reaction. The aqueous phase was analyzed for UDP-
Galf and UDP-Galp as described in Supplemental Data.
UV-Vis Spectroscopy Reactivity Assay
Each compound was dissolved in DMSO (10 mM solution). This
stock solution was added to 4 ml of a solution of 50 mM sodium
phosphate buffer (pH 7) to afford a final concentration of 40–50 mM
(maximum absorbance w1). The UV-Vis spectrum of this solution
was taken (Cary 50 Scan UV-Visible Spectrophotometer). Next,
DTT (12.3 mg) was added (final concentration 20 mM), and the reac-
tion was monitored at 1, 5, 30, and 60 min.
UV-Vis Spectroscopy Reversibility Assay
Compound 6 was dissolved in DMSO (10 mM solution). This stock
solution was added to 4 ml of a 50 mM sodium phosphate buffer
(pH 7) to afford a final concentration of 40 mM. The UV-Vis spectrum
of this solution was taken (Cary 50 Scan UV-Visible Spectrophotom-
eter). Next, 17.6 ml (11 equiv.) of a 10 mM solution of DTT was added,
and the reaction was monitored at 1 min and every 5 min for the first
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DTT in sodium phosphate buffer was monitored as a control.
Docking and Modeling Studies
Each small molecule was minimized in Sybyl 7.0 Base by first com-
puting charges with Gasteiger-Hu¨ckel. Minimization was performed
by the Conjugate Gradient method (Tripos force field) terminating
when the gradient energy was <0.01 kcal/mol. The minimized small
molecules were exported into DeLano Scientific LLC PyMol. The
small molecules were docked by manually placing the target com-
pounds within the putative active site. Best fit was determined
based upon sterics and relevant amino acid side chain interactions.
Synthesis of 32
General synthetic procedures are available as Supplemental Data.
Rhodanine (300 mg, 2.52 mmol) and sodium acetate (50 mg) were
dissolved in acetic acid (3.4 ml). m-bromobenzaldehyde (580 ml,
4.95 mmol) was added and the reaction was heated at reflux over-
night. Ice was added to the reaction, and the resulting precipitant
isolated by filtration (wash with cold water 23). The orange solid
was dried under reduced pressure and purified by flash chromatog-
raphy (silica, 3:1 hexanes:ethyl acetate) to give 234 mg (35% yield) of
a bright orange solid:1H-NMR (300 MHz, d6-DMSO) d 13.91 (bs, 1 H),
7.83 (t, 1 H, J = 1.5 Hz), 7.69 (dt, 1 H J = 7.8, 1.5 Hz), 7.63 (s, 1 H), 7.56
(d, 1 H, J = 7.8 Hz), 7.49 (t, 1 H, J = 7.8 Hz) ppm; 13C NMR (75 MHz,
d6-DMSO) d 195.3, 169.1, 135.3, 133.1, 133.0, 131.4, 129.7, 128.4,
127.3, 122.5 ppm; EMM (m/z) [M + H] calcd. for C10H6BrNOS2
298.9074, found 298.9059.
General Procedure for Solid-Phase Synthesis
of the Thiazolidinones
All resin reactions were performed in fritted vessels (Biorad). An
Fmoc-protected amino acid (2 equiv.) and cesium iodide (2 equiv.)
were dissolved in DMF (4 ml) and added to 2-(4-bromomethyl-
phenoxy)ethyl polystyrene resin (400 mg, 1 equiv.) that had been
rinsed with DMF (33). DIPEA (2 equiv.) was added to the resin sus-
pension. The vessel was capped and gently agitated overnight on
a tube rotator. The resin was washed with the following sequence
of solvents three times: DMF (33), THF (33), CH2Cl2 (33), acetoni-
trile (33), and methanol (13). Next, the resin was washed with
DMF, and the Fmoc group was removed with a 1:4 solution of piper-
idine:DMF (5 ml) for 1 hr (monitored with Kaiser ninhydrin test) to give
intermediate 12. The resulting resin was again washed using the
above procedure. Thiocarbonyl diimidazole (5 equiv.) and triethyl-
amine (3 equiv.) were dissolved in CH2Cl2 (3 ml) and added to the
resin that had been washed with CH2Cl2 (33). The resulting suspen-
sion was agitated for 1 hr followed by washing with dry CH2Cl2 (wet
solvent resulted in formation of hydrolysis products). Methyl thiogly-
colate (5 equiv.) was dissolved in toluene (3 ml) and immediately
added to the resin. This suspension was agitated on the rotator
overnight to yield the rhodanine intermediate (13). Formation of the
heterocycle could be observed by a color change of the resin (turned
pale orange/red). The resin was washed by the above described pro-
cedure and dried under high vacuum for a minimum of 5 hr. Approx-
imately 15 mg of the resin was weighed into a microwave reaction
vessel. The desired aldehyde or ketone reaction partners (4 equiv.)
were dissolved in toluene (1 ml) and added to the reaction vessels.
Next, piperidine (200 ml) and acetic acid (133 ml) were added result-
ing in solidification of the solution. Each reaction was subjected to
microwave irradiation for 10 min (5 min ramp, 5 min hold) at 70C
with 100 watts of power (CEM Discovery monomodal microwave re-
actor, 300 W [maximum] power source). After the suspension cooled
to room temperature, the resin was transferred to a fritted vessel and
washed with the aforementioned sequence and dried under high
vacuum.
Library members were cleaved from the resin with a trifluoroacetic
acid (TFA):CH2Cl2 (50:50) solution (400 ml) at 50
C for 1 hr. The resin
was rinsed with additional TFA and CH2Cl2. Solvent was removed
under a stream of nitrogen to give crude products, 14. The orange
or red residue was dissolved in a minimum amount of acetonitrile
(w200 mM) to which the same volume of water was added. This so-
lution was loaded onto a reserved phase (C18) plug (Alltech C18 ex-
tract-clean column, 200 mg). The column was washed with two
volumes of water. Elution of the products was effected by additionof a 60% acetonitrile:water solution (w2 ml). The product was col-
lected, and the solvent removed under a stream of nitrogen. Com-
pounds were characterized by 1H-NMR spectroscopy and LC-MS
analysis (quantification of absorbance at 280 nm). Compounds 6,
16, and 17were analyzed by chiral HPLC (i-PrOH with 0.1% TFA:hex-
anes with 0.1% TFA, 5%–55% IPA over 50 min, CHIRALCEL OD
250 3 4.6 mm column from Daicel Chemical Industries, Ltd.) and
found to be racemic.
Supplemental Data
Supplemental Data include procedures for production of UGMKleb
[44], procedures for the determination of binding constants and
IC50 values [52], and general synthetic procedures. Also included
are the structures of thiazolidinone-based compounds with Kd
values %10 mM that did not show activity inhibition against UGM,
a gel depicting the purification of UGMMyco, and characterization
data for the directed library members. These data are available at
http://www.chembiol.com/cgi/content/full/13/8/825/DC1/.
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